A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Children and Adolescents With Increased Risk of Pneumococcal Disease
Latest Information Update: 26 Mar 2025
At a glance
- Drugs V 116 (Primary) ; PPSV-23
- Indications Pneumococcal infections
- Focus Adverse reactions; Pharmacodynamics; Registrational
- Acronyms STRIDE-13
- Sponsors Merck Sharp & Dohme
Most Recent Events
- 24 Mar 2025 Status changed from active, no longer recruiting to completed.
- 19 Sep 2024 Status changed from recruiting to active, no longer recruiting.
- 07 Aug 2024 Planned End Date changed from 12 Feb 2025 to 28 Feb 2025.